These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 37183212

  • 1. Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy.
    Cheng S, Wang J, Wang Y, Qi L, Li F, Liu J, Chen J, Fan Y, Xie L.
    Eur Radiol Exp; 2023 May 15; 7(1):22. PubMed ID: 37183212
    [Abstract] [Full Text] [Related]

  • 2. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF, Manrique C, Pun S, Liu JE, Mara E, Fleisher M, Patil S, Jones LW, Steingart RM, Hudis CA, Dang CT.
    Oncologist; 2016 Apr 15; 21(4):418-24. PubMed ID: 26984450
    [Abstract] [Full Text] [Related]

  • 3. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF, Singh JC, Wang R, Liu JE, Eaton A, Oeffinger KC, Steingart RM, Hudis CA, Dang CT.
    Oncologist; 2017 Jun 15; 22(6):642-647. PubMed ID: 28341761
    [Abstract] [Full Text] [Related]

  • 4. Cardiac function in women receiving dual anti-Her2 antibodies (trastuzumab and pertuzumab) combined with chemotherapy for breast cancer.
    Zekri J, Rasool H, Rizvi SAJ, Eldeeb H, Al-Gahmi A, Farag K, Rasmy A.
    Womens Health (Lond); 2023 Jun 15; 19():17455057231166837. PubMed ID: 37148305
    [Abstract] [Full Text] [Related]

  • 5. Cardiotoxicity of novel HER2-targeted therapies.
    Sendur MA, Aksoy S, Altundag K.
    Curr Med Res Opin; 2013 Aug 15; 29(8):1015-24. PubMed ID: 23692263
    [Abstract] [Full Text] [Related]

  • 6. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
    Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, Tian G, Kirkpatrick ID, Singal PK, Krahn M, Grenier D, Jassal DS.
    J Am Coll Cardiol; 2011 May 31; 57(22):2263-70. PubMed ID: 21616287
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of left atrial remodeling using cardiovascular magnetic resonance imaging in breast cancer patients treated with adjuvant trastuzumab.
    Huang F, Brezden-Masley C, Chan KKW, Barfett JJ, Kirpalani A, Deva DP, Jimenez-Juan L, Barthur A, Song L, Chacko B, Ng MY, Connelly K, Wong KCK, Yan AT.
    Eur Radiol; 2022 Jun 31; 32(6):4234-4242. PubMed ID: 34993574
    [Abstract] [Full Text] [Related]

  • 8. Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study.
    Gong IY, Ong G, Brezden-Masley C, Dhir V, Deva DP, Chan KKW, Graham JJ, Chow CM, Thavendiranathan P, Dai D, Ng MY, Barfett JJ, Connelly KA, Yan AT.
    Int J Cardiovasc Imaging; 2019 Apr 31; 35(4):653-662. PubMed ID: 30390170
    [Abstract] [Full Text] [Related]

  • 9. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
    Houbois CP, Nolan M, Somerset E, Shalmon T, Esmaeilzadeh M, Lamacie MM, Amir E, Brezden-Masley C, Koch CA, Thevakumaran Y, Yan AT, Marwick TH, Wintersperger BJ, Thavendiranathan P.
    JACC Cardiovasc Imaging; 2021 May 31; 14(5):962-974. PubMed ID: 33248962
    [Abstract] [Full Text] [Related]

  • 10. Comprehensive Cardiovascular Magnetic Resonance Tissue Characterization and Cardiotoxicity in Women With Breast Cancer.
    Thavendiranathan P, Shalmon T, Fan CS, Houbois C, Amir E, Thevakumaran Y, Somerset E, Malowany JM, Urzua-Fresno C, Yip P, McIntosh C, Sussman MS, Brezden-Masley C, Yan AT, Koch CA, Spiller N, Abdel-Qadir H, Power C, Hanneman K, Wintersperger BJ.
    JAMA Cardiol; 2023 Jun 01; 8(6):524-534. PubMed ID: 37043251
    [Abstract] [Full Text] [Related]

  • 11. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    Arciniegas Calle MC, Sandhu NP, Xia H, Cha SS, Pellikka PA, Ye Z, Herrmann J, Villarraga HR.
    BMC Cancer; 2018 Oct 25; 18(1):1037. PubMed ID: 30359235
    [Abstract] [Full Text] [Related]

  • 12. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H, Tryfonidis K, Dal Lago L, Vuylsteke P, Curigliano G, Waters S, Brouwers B, Altintas S, Touati N, Cardoso F, Brain E.
    Lancet Oncol; 2018 Mar 25; 19(3):323-336. PubMed ID: 29433963
    [Abstract] [Full Text] [Related]

  • 13. Diagnostic and Prognostic Value of Myocardial Work Indices for Identification of Cancer Therapy-Related Cardiotoxicity.
    Calvillo-Argüelles O, Thampinathan B, Somerset E, Shalmon T, Amir E, Steve Fan CP, Moon S, Abdel-Qadir H, Thevakumaran Y, Day J, Woo A, Wintersperger BJ, Marwick TH, Thavendiranathan P.
    JACC Cardiovasc Imaging; 2022 Aug 25; 15(8):1361-1376. PubMed ID: 35926895
    [Abstract] [Full Text] [Related]

  • 14. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients.
    Keramida K, Farmakis D, Bingcang J, Sulemane S, Sutherland S, Bingcang RA, Ramachandran K, Tzavara C, Charalampopoulos G, Filippiadis D, Kouris N, Nihoyannopoulos P.
    Eur J Heart Fail; 2019 Apr 25; 21(4):529-535. PubMed ID: 30811091
    [Abstract] [Full Text] [Related]

  • 15. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
    Lynce F, Barac A, Tan MT, Asch FM, Smith KL, Dang C, Isaacs C, Swain SM.
    Oncologist; 2017 May 25; 22(5):518-525. PubMed ID: 28314836
    [Abstract] [Full Text] [Related]

  • 16. Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer.
    Zhang L, Wang Y, Meng W, Zhao W, Tong Z.
    Sci Rep; 2022 Aug 22; 12(1):14312. PubMed ID: 35995984
    [Abstract] [Full Text] [Related]

  • 17. Cardiac magnetic resonance imaging-based myocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated with trastuzumab: A pilot study to evaluate the feasibility of the method.
    Nakano S, Takahashi M, Kimura F, Senoo T, Saeki T, Ueda S, Tanno J, Senbonmatsu T, Kasai T, Nishimura S.
    Cardiol J; 2016 Aug 22; 23(3):270-80. PubMed ID: 27173679
    [Abstract] [Full Text] [Related]

  • 18. 2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab.
    Bouwer NI, Liesting C, Kofflard MJM, Brugts JJ, Kock MCJ, Kitzen JJEM, Levin MD, Boersma E.
    Cardiovasc Ultrasound; 2021 Nov 09; 19(1):35. PubMed ID: 34753503
    [Abstract] [Full Text] [Related]

  • 19. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D.
    Lancet Oncol; 2018 Jan 09; 19(1):115-126. PubMed ID: 29175149
    [Abstract] [Full Text] [Related]

  • 20. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.
    de Azambuja E, Agostinetto E, Procter M, Eiger D, Pondé N, Guillaume S, Parlier D, Lambertini M, Desmet A, Caballero C, Aguila C, Jerusalem G, Walshe JM, Frank E, Bines J, Loibl S, Piccart-Gebhart M, Ewer MS, Dent S, Plummer C, Suter T, APHINITY Steering Committee and Investigators.
    ESMO Open; 2023 Feb 09; 8(1):100772. PubMed ID: 36681013
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.